Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells

Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexFemale
Age18-90
SponsorMeir Medical Center

About this trial

Recently the general medical literature has become aware that the use of certain long-acting insulin analogues could potentially increase cancer risk.During the last few years the investigators group generated information of both scientific and clinical relevance on the proliferative and anti-apoptotic actions of insulin analogues. The goal of this project is to evaluate the hypothesis that the proliferative and signalling activities elicited by insulin analogues may have a impact on tumor behavior. In this study the investigators will asses the biological actions of insulin analogs in primary tumor cells of endometrial and colon cancer.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with Endometrial and Colon Cancer

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Tissue sample from tumor

    Other intervention

    Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.

Treatment groups

No treatment groups listed

Trial outcomes

This trial has no outcomes listed.

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Meir Medical Center

Lead sponsor

Tel Aviv University

Collaborator